Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence,<span><span><span style="color:black;"> </span></span...Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence,<span><span><span style="color:black;"> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">principally from epithelial origen. The high expression of EGFR in this tumor leads to the search for therapeutic alternatives. An Expanded Access Clinical Program was carried out in parallel groups, randomized, multicenter and prospective study, to evaluate the survival of patients with advanced cervical carcinoma, without therapeutic alternative, who would be treated with the therapeutic vaccine CIMAvax-EGF<sup></sup></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="white-space:nowrap;"><sup>®</sup></span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">, the humanized mAb nimotuzumab </span><span style="font-family:Verdana;">or</span><span style="font-family:Verdana;"> the combination of both products, which targeted EGF and EGFR respectively. The patients were included between 2008 and 2010 with </span><span style="font-family:Verdana;">a more</span><span style="font-family:Verdana;"> than five years follow-up. The results show that the serious adverse events related to the experimental treatments were 0.9</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">%</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">;1.1</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">%</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> and 2.6% and a median ITT survival of 9.1, 23.5, and 16.3 months for CIMAvax-EGF<sup></sup></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="white-space:nowrap;"><sup>®</sup></span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">, nimotuzumab </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> the combination of both, respectively. Thus fulfilling the hypothesis of safety and efficacy proposed in the investigation was achieved. The three therapeutic regimens achieved overall survival rates greater than 35% at 60 months, encouraging results for advanced uterine cervical cancer. A phase III clinical trial is proposed to consolidate these results in a greater number of patients with nimotuzumab as </span><span style="font-family:Verdana;">study</span><span style="font-family:Verdana;"> drug. <p> <br /> </p> </span></span></span></span>展开更多
文摘Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence,<span><span><span style="color:black;"> </span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">principally from epithelial origen. The high expression of EGFR in this tumor leads to the search for therapeutic alternatives. An Expanded Access Clinical Program was carried out in parallel groups, randomized, multicenter and prospective study, to evaluate the survival of patients with advanced cervical carcinoma, without therapeutic alternative, who would be treated with the therapeutic vaccine CIMAvax-EGF<sup></sup></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="white-space:nowrap;"><sup>®</sup></span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">, the humanized mAb nimotuzumab </span><span style="font-family:Verdana;">or</span><span style="font-family:Verdana;"> the combination of both products, which targeted EGF and EGFR respectively. The patients were included between 2008 and 2010 with </span><span style="font-family:Verdana;">a more</span><span style="font-family:Verdana;"> than five years follow-up. The results show that the serious adverse events related to the experimental treatments were 0.9</span></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">%</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">;1.1</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">%</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> and 2.6% and a median ITT survival of 9.1, 23.5, and 16.3 months for CIMAvax-EGF<sup></sup></span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="white-space:nowrap;"><sup>®</sup></span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">, nimotuzumab </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> the combination of both, respectively. Thus fulfilling the hypothesis of safety and efficacy proposed in the investigation was achieved. The three therapeutic regimens achieved overall survival rates greater than 35% at 60 months, encouraging results for advanced uterine cervical cancer. A phase III clinical trial is proposed to consolidate these results in a greater number of patients with nimotuzumab as </span><span style="font-family:Verdana;">study</span><span style="font-family:Verdana;"> drug. <p> <br /> </p> </span></span></span></span>
